Ross Wallace

478 total citations
9 papers, 30 citations indexed

About

Ross Wallace is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Ross Wallace has authored 9 papers receiving a total of 30 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 3 papers in Pathology and Forensic Medicine and 3 papers in Oncology. Recurrent topics in Ross Wallace's work include Cancer Mechanisms and Therapy (3 papers), Advanced Breast Cancer Therapies (2 papers) and Computational Drug Discovery Methods (2 papers). Ross Wallace is often cited by papers focused on Cancer Mechanisms and Therapy (3 papers), Advanced Breast Cancer Therapies (2 papers) and Computational Drug Discovery Methods (2 papers). Ross Wallace collaborates with scholars based in United States and Spain. Ross Wallace's co-authors include Karyn Bouhana, Eric Brown, Kevin Ebata, James F. Blake, L. Williams, Shannon L. Winski, Guy Vigers, Brian B. Tuch, Tony Morales and S. Michael Rothenberg and has published in prestigious journals such as Blood, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Ross Wallace

6 papers receiving 28 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ross Wallace United States	3	15	15	12	11	10	9	30
Hege Russnes Norway	3	17 1.1×	13 0.9×	9 0.8×	5 0.5×	7 0.7×	4	30
Jakob Sidenius Johansen Denmark	4	12 0.8×	14 0.9×	8 0.7×	19 1.7×	18 1.8×	10	43
Elen Höglander United Kingdom	4	10 0.7×	19 1.3×	6 0.5×	13 1.2×	9 0.9×	5	32
Ruzanna Papyan Armenia	4	18 1.2×	9 0.6×	9 0.8×	11 1.0×	7 0.7×	14	55
Flavia Cantile Italy	3	23 1.5×	24 1.6×	7 0.6×	15 1.4×	10 1.0×	3	41
Shivam Mathura United States	3	8 0.5×	24 1.6×	13 1.1×	9 0.8×	16 1.6×	5	30
Briana M. Hudson United States	3	10 0.7×	22 1.5×	8 0.7×	12 1.1×	12 1.2×	3	34
Rajesh Rawal Germany	3	19 1.3×	18 1.2×	16 1.3×	10 0.9×	12 1.2×	3	78
Kunal Gawri United States	3	17 1.1×	15 1.0×	7 0.6×	7 0.6×	5 0.5×	9	25
Nicklas Pfanzelter United States	3	18 1.2×	22 1.5×	11 0.9×	22 2.0×	6 0.6×	5	47

Countries citing papers authored by Ross Wallace

Since Specialization

Citations

This map shows the geographic impact of Ross Wallace's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ross Wallace with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ross Wallace more than expected).

Fields of papers citing papers by Ross Wallace

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ross Wallace. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ross Wallace. The network helps show where Ross Wallace may publish in the future.

Co-authorship network of co-authors of Ross Wallace

This figure shows the co-authorship network connecting the top 25 collaborators of Ross Wallace. A scholar is included among the top collaborators of Ross Wallace based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ross Wallace. Ross Wallace is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Lee, Janice Y., Nathan A. Brooks, Brandon Antonakos, et al.. (2024). Abstract 3230: Discovery of selective BRM (SMARCA2) ATPase inhibitors for the treatment of BRG1 (SMARCA4) mutant cancers. Cancer Research. 84(6_Supplement). 3230–3230. 1 indexed citations

Lee, Janice Y., Nathan A. Brooks, Brandon Antonakos, et al.. (2024). Abstract PR015: Discovery of LY4050784 (FHD-909), a selective BRM (SMARCA2) ATPase inhibitor for the treatment of BRG1(SMARCA4) mutant cancers. Molecular Cancer Therapeutics. 23(6_Supplement). PR015–PR015. 1 indexed citations

Ren, Li, David Moreno‐Mateos, Brian R. Baer, et al.. (2024). Identification of the Clinical Candidate PF-07284890 (ARRY-461), a Highly Potent and Brain Penetrant BRAF Inhibitor for the Treatment of Cancer. Journal of Medicinal Chemistry. 67(15). 13019–13032. 1 indexed citations

Li, Binghui, Trent R. Stewart, Tao Wang, et al.. (2023). Abstract B115: Preclinical characterization of LY3962673, an orally bioavailable, highly potent, and selective KRAS G12D inhibitor. Molecular Cancer Therapeutics. 22(12_Supplement). B115–B115.

Bouhana, Karyn, Walter E. DeWolf, Li Ren, et al.. (2021). Abstract 1473: Nonclinical development of PF-07284890 (ARRY-461), a potent, brain-penetrant, small molecule inhibitor of BRAF V600-mutation-driven tumors in vitro and in vivo. Cancer Research. 81(13_Supplement). 1473–1473. 4 indexed citations

Brandhuber, Barbara J., Brian B. Tuch, Kevin Ebata, et al.. (2016). The development of a potent, KDR/VEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers. European Journal of Cancer. 69. S144–S144. 17 indexed citations

Brandhuber, Barbara J., Nisha Nanda, Julia Haas, et al.. (2015). Abstract B192: Identification and characterization of highly potent and selective RET kinase inhibitors for the treatment of RET-driven cancers. Molecular Cancer Therapeutics. 14(12_Supplement_2). B192–B192. 5 indexed citations

Groß, Stefan, John Robinson, Shelley Allen, et al.. (2008). Characterization of the Effects of Pim Kinase Inhibition on Multiple Oncogene-Driven Cell Lines. Blood. 112(11). 2662–2662. 1 indexed citations

Eiduson, Samuel, et al.. (1953). Effect of Electroshock Therapy on Blood Lactic Acid and Pyruvic Acid. Experimental Biology and Medicine. 84(2). 364–367.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact